NCT07674134 Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
| NCT ID | NCT07674134 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Princesse Grace |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-04-23 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2024-04-23 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response. The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
Eligibility Criteria
Inclusion Criteria: * Patient aged over 18 years * Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria * Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations * Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure. Exclusion Criteria: * No contraindication to a bDMARD * Not stable dose of corticosteroids in the 4 weeks preceding enrollment * Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment * Prior treatment with a JAK inhibitor * Patient unable to be followed-up in the study during 6 months * Minors or adults under guardianship or curatorship, or deprived of their liberty * Pregnant or breastfeeding patient * Patient refusing to use an effective method of contraception for the duration of the study * Person not affiliated with a social security scheme.
Contact & Investigator
Olivier BROCQ, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Princesse Grace
Frequently Asked Questions
Who can join the NCT07674134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07674134 currently recruiting?
Yes, NCT07674134 is actively recruiting participants. Contact the research team at recherche.clinique@chpg.mc for enrollment information.
Where is the NCT07674134 trial being conducted?
This trial is being conducted at Monaco, Monaco.
Who is sponsoring the NCT07674134 clinical trial?
NCT07674134 is sponsored by Centre Hospitalier Princesse Grace. The principal investigator is Olivier BROCQ, MD at Centre Hospitalier Princesse Grace. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.